Turning 65 in 2026? One wrong move in your initial enrollment period could substantially compromise your cancer care.
Consider this: Nearly 40% of Americans will face a cancer diagnosis, a risk that spikes with age. You deserve the best possible care as you confront those odds. A key to getting it is securing original Medicare plus Medigap and Part D before a critical seven-month window closes. The problem is that many people navigating the selection process don’t even know that such an interval exists.
In this window, anyone Medicare-eligible – regardless of health status – can obtain supplemental coverage without medical underwriting or added cost. Once it closes, insurers can require underwriting, meaning applicants must answer questions about preexisting conditions such as cancer, diabetes or heart disease and possibly be denied supplemental coverage. Based on those answers, insurers can legally deny coverage and raise rates precisely when patients need protection most.
To make the most of that window, focus on building your coverage deliberately. Original Medicare – funded by tax dollars – remains the strongest foundation, but only when combined with supplemental coverage and Part D, which covers pills.
Why are pills important? The future of cancer care is prescription oral pills. Chemotherapy infusions once dominated treatment, but today, targeted cancer therapies often come as pills – more effective and easier to take at home, yet extraordinarily expensive, often more than $10,000 a month. Without Part D, cancer patients risk crushing debt or disrupting treatment. Waiting to enroll adds penalties that raise long-term costs.
But even as you plan your own coverage choices, you must stay privy to shifts in the Medicare system. New federal experiments using artificial intelligence may reshape how Medicare works behind the scenes in the future.
Starting Jan. 1, six states – Arizona, New Jersey, Ohio, Oklahoma, Texas and Washington – implemented the Centers for Medicare and Medicaid Services’ Wasteful and Inappropriate Service Reduction Model, an AI-assisted program intended to streamline prior authorization reviews for efficiency in original Medicare.
In oncology, unnecessary delays can prove deadly. Consider the case of Tom, a Texas retiree whose case we previously wrote about. A three-month Medicare Advantage delay for pancreatic biopsy approval allowed his disease to progress from treatable to terminal. He racked up $17,000 in out-of-pocket costs for care after finally receiving approval. That pattern holds broadly: Between 2019 and 2023, over 80% of Medicare Advantage appeals across disease groups succeeded – but only after patients endured harmful delays fighting for essential care.
That said, seniors in the remaining 44 states should continue to receive original Medicare as designed. But with WISeR running through late 2031 as a CMS Innovation Center test, more states could adopt similar prior authorization requirements in coming years, further eroding original Medicare’s advantages.
In our oncology and public health work, we’ve witnessed inadequate coverage decisions transform treatable cancers into fatal ones. Medicare isn’t a gift – it’s what you’ve funded through decades of payroll taxes. In 2026, claim it: Enroll in original Medicare during your seven-month initial enrollment period, pair it with Medigap and Part D, and lock in the cancer care protections you’ve earned for life.
